EUCTR2021-000731-31-NL进行中（未招募）1 期
Targeting the beta-2 adrenergic pathway to improve skeletal muscleglucose uptake in obese humans - Clenbuterol study
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Male or (postmenopausal; defined as 1 year after the last cycle) female;
- •2.Age between 40-70 years;
- •3.BMI: 27-35 kg/m2;
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 40
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 40
排除标准
- •1.Not meeting all inclusion criteria
- •2.Cardiovascular disease (determined by means of questionnaires, heart rate/blood pressure measurements and an ECG)
- •3.Respiratory diseases (including asthma, bronchitis and COPD);
- •4.Unstable body weight (weight gain or loss > 5 kg in the last three months);
- •5.Intention to lose or gain body weight (e.g. with caloric restriction or physical activity)
- •6.Excessive alcohol and/or drug abuse;
- •7.Hypokalaemia;
- •8.Hyperthyroidism
- •9.Anaemia;
- •10.Epilepsy;
- •11.Smoking;
- •12.Renal and/or liver insufficiency;
- •13.Diagnosed with type 1 or type 2 diabetes mellitus;
- •14.Any contra-indications to MRI scanning. These contra-indications include patients with:
- •a.Electronic implants such as pacemakers, defibrillators or neurostimulators
- •b.Central nervous system aneurysm clip
- •c.Some hearing aids (such as cochlear implant) and artificial (heart) valves which are contraindicated for MRI/MRS
- •d.Iron containing corpora aliena in the eye or brains
- •e.Claustrophobia
- •15.Participation in another biomedical study within 1 month before the first study visit, possibly interfering with the study results;
- •16.Medication use known to hamper subject’s safety during the study procedures; ?
- •17.Subjects who do not want to be informed about unexpected medical findings; ?
- •18.Subjects who do not want that their treating physician to be informed;
- •19.Inability to participate and/or complete the required measurements;
- •20.Participation in organised or structured physical exercise;
- •21.Any condition, disease or abnormal laboratory test result that, in the opinion of the Investigator, would interfere with the study outcome, affect trial participation or put the subject at undue risk;
研究者
相似试验
已完成
2 期
Targeting the beta-2 adrenergic pathway to improve skeletal muscle glucose uptake in obese humansdiabetesNL-OMON51975niversiteit Maastricht40
进行中（未招募）
1 期
Investigation of a new way for sugar uptake by the skeletal muscle.EUCTR2018-004245-16-NLMaastricht University16
已完成
2 期
Targeting the beta-2 adrenergic pathway to improve skeletal muscle glucose uptake in healthy humanstype 2 diabetes10018424diabetesNL-OMON50072niversiteit Maastricht23
进行中（未招募）
1 期
Activation of human brown adipose tissue with the use of salbutamolObesity, overweight, lipid- and glucose metabolismMedDRA version: 20.0Level: LLTClassification code 10029885Term: Obesity, unspecifiedSystem Organ Class: 100000004861EUCTR2020-004059-34-NLeiden University Medical Center10
已完成
不适用
The beta-2 adrenergic receptor in human BATNL-OMON27924A10